Clinical Trial Update: Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study assessing sequential infusion of CD19- and CD20-directed CAR-T cells in relapsed or refractory B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• CD19-directed CAR-T cells (CD19-directed chimeric antigen receptor T cells)
• CD20-directed CAR-T cells (CD20 CAR-T cells)

Snippet

Sponsor: Shanghai Longyao Biotechnology Inc., Ltd. | Conditions: Recurrent or Refractory B Cell Malignancy | Phase 1, Phase 2 | Status: UNKNOWN